Announced details
Solid tumors and oncology. Phase I clinical trials and late Phase Ib/Phase II clinical trials in combination with other anticancer drugs.
The mean ΔQTcF and the upper bound of the 90% confidence interval were below 10 milliseconds.
Jointly created E7386. Eisai Co.,Ltd. is conducting the clinical trials of E7386 and will make the presentation at ASCO.
Head office: Bunkyo-ku, Tokyo. Other company information: Not disclosed.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
ASCO Annual Meeting 2026. Abstract number: e24005.
| Item | Details |
|---|---|
| Names of Products / Services Covered | E7386 (an orally administered CBP/β-catenin interaction inhibitor) |
| Counterparty | Eisai Co.,Ltd. |
| Counterparty overview | Head office: Bunkyo-ku, Tokyo. Other company information: Not disclosed. |
| Relationship with the Company | Jointly created E7386. Eisai Co.,Ltd. is conducting the clinical trials of E7386 and will make the presentation at ASCO. |
| Applicable area | Solid tumors and oncology. Phase I clinical trials and late Phase Ib/Phase II clinical trials in combination with other anticancer drugs. |
| Quantitative Effects | The mean ΔQTcF and the upper bound of the 90% confidence interval were below 10 milliseconds. |
| Source | ASCO Annual Meeting 2026. Abstract number: e24005. |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Concentration–QTc modeling analysis using plasma concentration and ECG data from the Phase I clinical trial found no clinically meaningful effects on cardiac conduction or heart rate within the evaluated dose range, and no significant association between plasma concentration and ΔQTcF.